New biologics for psoriasis and psoriatic arthritis

Dermatologic Therapy

Volumn 22, Issue 1, 2009, Pages 56-60

  Rozenblit, Mariya ^a   Lebwohl, Mark ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

ABT 874; Certolizumab; Golimumab; Psoriasis; Psoriatic arthritis; Ustekinumab

Indexed keywords

ABT 874; ADALIMUMAB; ALEFACEPT; CALCINEURIN INHIBITOR; CERTOLIZUMAB PEGOL; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DITHRANOL; EFALIZUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 23 ANTIBODY; ISONIAZID; LIVE VACCINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RETINOID; SALAZOSULFAPYRIDINE; SALICYLIC ACID; TAR; UNCLASSIFIED DRUG; USTEKINUMAB;

BASAL CELL CARCINOMA; BIOLOGICAL THERAPY; BONE MARROW TOXICITY; CLINICAL EVALUATION; CLINICAL TRIAL; CROHN DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; HEART FAILURE; HUMAN; IMMUNE RESPONSE; INJECTION SITE REACTION; LIVER TOXICITY; LOWER RESPIRATORY TRACT INFECTION; OCCUPATIONAL THERAPY; PHOTOCHEMOTHERAPY; PHYSIOTHERAPY; PREVALENCE; PROSTATE CANCER; PSORIASIS; PSORIATIC ARTHRITIS; RADIODIAGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SYMPTOM; TUBERCULOSIS; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; PREVALENCE; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 60649092609     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2008.01216.x     Document Type: Review

References (32)

1. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004 : 9 : 136 139.
2. Christophers E, Sterry W. Psoriasis. In : Fizpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, eds. Dermatology in general medicine. New York, NY : McGraw-Hill, 1993 : 489 514.
3. Koo J, Lee E, Lee CS, Lebwohl M. Psoriasis. J Am Acad Dermatol 2004 : 50 : 613 622.
4. De Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004 : 9 : 140 147.
5. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005 : 64 (Suppl. 2 ii14 ii17.
6. Landells I, Maccallum C, Khraishi M. The role of the dermatologist in identification and treatment of the early stages of psoriatic arthritis. Skin Therapy Lett 2008 : 13 (4 4 7.
7. Horn EJ, Fox KM, Patel V, Chiou CF, Dann F, Lebwohl M. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation Survey. J Am Acad Dermatol 2007 : 57 (6 957 962.
8. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008 : 58 (5 851 864.
9. Tam LS, Tomlinson B, Chu TT, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls - the role of inflammation. Rheumatology (Oxford) 2008 : 47 (5 718 723.
10. Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 2008 : 67 (6 855 859.
11. Abu-Shakra M, Gladman DD, Thorne JC, Long J, Gough J, Farewell VT. Long term methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995 : 22 (2 241 245.
12. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991 : 90 : 711 716.
13. Myers WA, Gottlieb AB, Mease P. Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol 2006 : 24 (5 438 447.
14. Kavanaugh A, McInnes I, Mease, P, et al. Golimumab, a new human TNF-alpha antibody administered as a monthly subcutaneous injection in psoriatic arthritis: 24 week efficacy and safety results of the randomized, placebo controlled GO-REVEAL study. Abstract presented at the European League Against Rheumatism, 2008, Paris.
15. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999 : 53 (3 457 465.
16. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 2003 : 107 (25 3133 3140.
17. Lebwohl M, Bagel J, Gelfand JM, et al. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 2008 : 58 (1 94 105.
18. Melmed GY, Targan SR, Yasothan U, Hanicq D, Kirkpatrick P. Certolizumab pegol. Nat Rev Drug Discov 2008 : 7 (8 641 642.
19. Fantuzzi F, Del Giglio M, Gisondi P, Girolomoni G. Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. Expert Opin Ther Targets 2008 : 12 (9 1085 1096.
20. Choy EH, Hazleman B, Smith M, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology 2002 : 41 (10 1133 1137.
21. Robertson MJ, Ritz J. Interleukin 12: basic biology and potential applications in cancer treatment. Oncologist 1996 : 1 : 88 97.
22. Capon F, Di Meglio P, Szaub J, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007 : 122 (2 201 206.
23. Toichi E, Torres G, McCormick TS, et al. An anti-IL p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006 : 177 : 4917 4926.
24. Kauffman CL, Aria N, Toichi E, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004 : 123 : 1037 1044.
25. Gottlieb AB, Cooper KD, McCormick TS, et al. A phase I, double blind placebo controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin 2007 : 23 (5 1081 1092.
26. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007 : 356 (6 580 592.
27. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis. Arch Dermatol 2008 : 144 (2 200 207.
28. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double blind, placebo-controlled trial (PHOENIX 1). Lancet 2008 : 371 : 1665 1674.
29. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008 : 371 (9625 1675 1684.
30. Gottlieb AB, Mendelsohn, A. Shen YK, Menter A. Ustekinumab, a human interleukin-12/23 monoclonal antibody, significantly improves overall skin response and health related quality of life in patients with psoriatic arthritis. Abstracts of the Annual Congress of the European Academy of Dermatology and Venereology; September 17 20, 2008 Paris, France.
31. Gottlieb AB, Mendelsohn A., Shen YK, Menter A. Randomized, placebo-controlled phase 2 study of ustekinumab, a human interleukin 12/23 monoclonal antibody, in psoriatic arthritis. Abstracts of the American Academy of Dermatology Summer Meeting; July 30-August 3, 2008 Chicago, Illinois.
32. Kavanaugh A, Menter A, Han C, Mendelsohn A, Schenkel B, Gottlieb AB. Ustekinumab results in rapid, sustained and clinically meaningful improvements in physical disability and quality of life in patients with psoriatic arthritis: Results from a randomized and placebo-controlled phase II trial. Abstracts of the Annual Congress of the European Academy of Dermatology and Venereology; September 17 20, 2008 Paris, France.